



## **Intercell AG Appoints Two Senior Vaccine Executives to the Supervisory Board**

**Vienna, Austria, January 17th , 2005** – Intercell AG is pleased to announce that Emilio Emini and James R. Sulat will join Intercell’s Supervisory Board with effect from today.

**Alexander von Gabain, CEO Intercell** states “We are proud to have Emilio Emini and James Sulat on our Supervisory Board. Having been in leading positions at Merck&Co, Inc. and Chiron Cooperation, they bring international and especially US experience in large-scale vaccine development combined with top class finance and capital market know how from their distinguished careers to Intercell”.

Michael Stranz from Kapital&Wert, an Austrian private equity fund, will leave Intercell’s Supervisory Board.

**Emilio A. Emini, Ph.D.**, is a globally recognized expert in the field of vaccines. Currently he is Senior Vice President and Chief of Vaccine Development at the International AIDS Vaccine Initiative (IAVI) where he oversees IAVI's partnership programs to develop an AIDS vaccine. He joined IAVI earlier this year after 20 years at **Merck & Co., Inc.**, where he gained recognition as one of the world's preeminent vaccine scientists and where he was responsible for leading the pharmaceutical giant's global vaccine research portfolio. Emilio Emini holds a Ph.D in Microbiology, Genetics and Biochemistry from Cornell University and a BS degree in Biology. He is author and co-author of more than 100 scientific publications and lecturer at renowned universities including the University of Pennsylvania. Additionally he served as member on several international recognized scientific committees and Editorial Boards including the Journal of Virology.

**James R. Sulat** is a senior executive and has a broad background within general management, finance, and strategy development. In his career he gained extensive experience in corporate governance and corporate development. Mr. Sulat served from 1998 to 2003 as the Chief Financial Officer of **Chiron Corporation**, a leading vaccine and biopharmaceutical company. Prior to joining Chiron, Mr. Sulat served from 1993 to 1998 as Chief Financial Officer of Stanford Health Services, the clinical healthcare delivery arm of the Stanford University Medical Center. In addition, Mr. Sulat was a management consultant with the Boston Consulting Group. Mr. Sulat received his undergraduate degree from Yale University and holds an M.B.A. and M.S. in Health Services Administration from Stanford University.



## **About Intercell**

Intercell is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prophylactic and therapeutic treatment of diseases with substantial unmet needs. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including Aventis Pasteur, Merck&Co., Inc., Scigen and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis about to enter Phase III, a vaccine for Hepatitis C undergoing Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. To date, Intercell has raised approximately Euro 100 million in external funding from international investors.

For more information please visit: [www.intercell.com](http://www.intercell.com)

## **Contact Intercell AG:**

### **Intercell AG**

Katharina Wieser  
Head of Corporate Communications  
Campus Vienna Biocenter 2  
A-1030 Vienna

P: +43-1-20620-303

Mail to: [kwieser@intercell.com](mailto:kwieser@intercell.com)

[www.intercell.com](http://www.intercell.com)

### **Brunswick**

Jon Coles/Wendel Verbeek/  
Laure Korenian-Chabert  
16 Lincoln's Inn Fields  
London EC2A 3ED  
United Kingdom

P: +44-(0)20-7404-5959

Mail to: [intercell@brunswickgroup.com](mailto:intercell@brunswickgroup.com)

*This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*